Baxalta now part of Shire
111
1
3
89
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
16.2%
18 terminated/withdrawn out of 111 trials
83.2%
-3.3% vs industry average
44%
49 trials in Phase 3/4
67%
60 of 89 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (111)
Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B
Role: lead
A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A
Role: lead
A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)
Role: lead
A Study of BAX 888 in Male Adults With Severe Hemophilia A
Role: lead
A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD)
Role: lead
A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A
Role: lead
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
Role: lead
Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP
Role: lead
RIXUBIS Drug Use-Result Survey (Japan)
Role: lead
ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD)
Role: lead
A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID)
Role: lead
A Study of ADVATE in People With Hemophilia A in India
Role: lead
A Study to Assess the Tolerability, Safety, and Pharmacokinetics of Subcutaneous Immune Globulin Infusion 10% (Human) With Recombinant Human Hyaluronidase (HYQVIA/HyQvia) With Ramp-up and No Ramp-up Dosing in Healthy Adult Participants
Role: lead
Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects
Role: lead
A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Role: lead
FEIBA Reconstitution Volume Reduction and Faster Infusion Study (FEIBA STAR)
Role: lead
Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects
Role: lead
Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)
Role: lead
RIXUBIS PMS India (RIXUBIS PMS)
Role: lead
Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice
Role: lead